CN101128218A - 菁染料用于诊断增生性疾病的用途 - Google Patents
菁染料用于诊断增生性疾病的用途 Download PDFInfo
- Publication number
- CN101128218A CN101128218A CNA2006800014277A CN200680001427A CN101128218A CN 101128218 A CN101128218 A CN 101128218A CN A2006800014277 A CNA2006800014277 A CN A2006800014277A CN 200680001427 A CN200680001427 A CN 200680001427A CN 101128218 A CN101128218 A CN 101128218A
- Authority
- CN
- China
- Prior art keywords
- dysplasia
- tumor
- cancer
- carcinoma
- hypoplasia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000003745 diagnosis Methods 0.000 title claims abstract description 29
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 20
- 201000010099 disease Diseases 0.000 title claims abstract description 18
- 230000002062 proliferating effect Effects 0.000 title claims abstract description 17
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 title abstract description 10
- 239000000975 dye Substances 0.000 title description 19
- 230000037396 body weight Effects 0.000 claims abstract description 37
- 206010028980 Neoplasm Diseases 0.000 claims description 83
- 150000001875 compounds Chemical class 0.000 claims description 58
- 206010058314 Dysplasia Diseases 0.000 claims description 35
- 201000011510 cancer Diseases 0.000 claims description 32
- 239000000203 mixture Substances 0.000 claims description 21
- 230000003902 lesion Effects 0.000 claims description 20
- 210000002745 epiphysis Anatomy 0.000 claims description 12
- 230000015689 metaplastic ossification Effects 0.000 claims description 12
- 206010006187 Breast cancer Diseases 0.000 claims description 11
- 208000026310 Breast neoplasm Diseases 0.000 claims description 11
- 150000003839 salts Chemical class 0.000 claims description 11
- 206010054949 Metaplasia Diseases 0.000 claims description 10
- 201000008275 breast carcinoma Diseases 0.000 claims description 10
- 239000012634 fragment Substances 0.000 claims description 10
- 230000012010 growth Effects 0.000 claims description 10
- 210000001185 bone marrow Anatomy 0.000 claims description 8
- 230000008859 change Effects 0.000 claims description 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 8
- 238000012546 transfer Methods 0.000 claims description 8
- 230000027455 binding Effects 0.000 claims description 7
- 230000008878 coupling Effects 0.000 claims description 7
- 238000010168 coupling process Methods 0.000 claims description 7
- 238000005859 coupling reaction Methods 0.000 claims description 7
- 238000011161 development Methods 0.000 claims description 7
- 230000018109 developmental process Effects 0.000 claims description 7
- 210000000056 organ Anatomy 0.000 claims description 7
- 206010008263 Cervical dysplasia Diseases 0.000 claims description 6
- 206010025421 Macule Diseases 0.000 claims description 6
- 208000007951 cervical intraepithelial neoplasia Diseases 0.000 claims description 6
- 108020004707 nucleic acids Proteins 0.000 claims description 6
- 102000039446 nucleic acids Human genes 0.000 claims description 6
- 210000000988 bone and bone Anatomy 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 210000003981 ectoderm Anatomy 0.000 claims description 5
- 150000007523 nucleic acids Chemical class 0.000 claims description 5
- 229920001184 polypeptide Polymers 0.000 claims description 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 5
- 208000023514 Barrett esophagus Diseases 0.000 claims description 4
- 206010020649 Hyperkeratosis Diseases 0.000 claims description 4
- 208000001126 Keratosis Diseases 0.000 claims description 4
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 4
- 208000004453 Retinal Dysplasia Diseases 0.000 claims description 4
- 230000002159 abnormal effect Effects 0.000 claims description 4
- 230000001419 dependent effect Effects 0.000 claims description 4
- 208000002169 ectodermal dysplasia Diseases 0.000 claims description 4
- 208000030533 eye disease Diseases 0.000 claims description 4
- 230000003054 hormonal effect Effects 0.000 claims description 4
- 208000008084 monostotic fibrous dysplasia Diseases 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 208000028591 pheochromocytoma Diseases 0.000 claims description 4
- 238000012216 screening Methods 0.000 claims description 4
- 230000001568 sexual effect Effects 0.000 claims description 4
- 210000001550 testis Anatomy 0.000 claims description 4
- 201000009273 Endometriosis Diseases 0.000 claims description 3
- 101000583175 Homo sapiens Prolactin-inducible protein Proteins 0.000 claims description 3
- 206010020880 Hypertrophy Diseases 0.000 claims description 3
- 208000003445 Mouth Neoplasms Diseases 0.000 claims description 3
- 102100030350 Prolactin-inducible protein Human genes 0.000 claims description 3
- 210000000981 epithelium Anatomy 0.000 claims description 3
- 208000020082 intraepithelial neoplasia Diseases 0.000 claims description 3
- 239000003446 ligand Substances 0.000 claims description 3
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims description 3
- 201000001441 melanoma Diseases 0.000 claims description 3
- 210000004877 mucosa Anatomy 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 201000001514 prostate carcinoma Diseases 0.000 claims description 3
- 206010000501 Acne conglobata Diseases 0.000 claims description 2
- 206010056951 Actinic cheilitis Diseases 0.000 claims description 2
- 206010003139 Arsenical keratosis Diseases 0.000 claims description 2
- 206010003571 Astrocytoma Diseases 0.000 claims description 2
- 208000023665 Barrett oesophagus Diseases 0.000 claims description 2
- 206010004272 Benign hydatidiform mole Diseases 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 208000013165 Bowen disease Diseases 0.000 claims description 2
- 208000019337 Bowen disease of the skin Diseases 0.000 claims description 2
- 208000009903 Camurati-Engelmann Syndrome Diseases 0.000 claims description 2
- 208000013627 Camurati-Engelmann disease Diseases 0.000 claims description 2
- 201000009030 Carcinoma Diseases 0.000 claims description 2
- 206010008724 Chondroectodermal dysplasia Diseases 0.000 claims description 2
- 201000000304 Cleidocranial dysplasia Diseases 0.000 claims description 2
- 208000032170 Congenital Abnormalities Diseases 0.000 claims description 2
- 206010010356 Congenital anomaly Diseases 0.000 claims description 2
- 206010010452 Congenital ectodermal dysplasia Diseases 0.000 claims description 2
- 206010061619 Deformity Diseases 0.000 claims description 2
- 208000005335 Dentin Dysplasia Diseases 0.000 claims description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 2
- 238000009007 Diagnostic Kit Methods 0.000 claims description 2
- 208000006586 Ectromelia Diseases 0.000 claims description 2
- 201000002650 Ellis-van Creveld syndrome Diseases 0.000 claims description 2
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 claims description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 2
- 208000000571 Fibrocystic breast disease Diseases 0.000 claims description 2
- 208000008961 Fibrous Dysplasia of Bone Diseases 0.000 claims description 2
- 206010016717 Fistula Diseases 0.000 claims description 2
- 208000003790 Foot Ulcer Diseases 0.000 claims description 2
- 208000010412 Glaucoma Diseases 0.000 claims description 2
- 208000032612 Glial tumor Diseases 0.000 claims description 2
- 206010018338 Glioma Diseases 0.000 claims description 2
- 208000029966 Hutchinson Melanotic Freckle Diseases 0.000 claims description 2
- 208000006937 Hydatidiform mole Diseases 0.000 claims description 2
- 208000008017 Hypohidrosis Diseases 0.000 claims description 2
- 208000037396 Intraductal Noninfiltrating Carcinoma Diseases 0.000 claims description 2
- 206010073094 Intraductal proliferative breast lesion Diseases 0.000 claims description 2
- 201000006165 Kuhnt-Junius degeneration Diseases 0.000 claims description 2
- 206010024218 Lentigo maligna Diseases 0.000 claims description 2
- 206010024434 Lichen sclerosus Diseases 0.000 claims description 2
- 206010024503 Limb reduction defect Diseases 0.000 claims description 2
- 208000005446 Lupus vulgaris Diseases 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 206010025327 Lymphopenia Diseases 0.000 claims description 2
- 201000001853 McCune-Albright syndrome Diseases 0.000 claims description 2
- 206010029260 Neuroblastoma Diseases 0.000 claims description 2
- 208000004286 Osteochondrodysplasias Diseases 0.000 claims description 2
- 206010031252 Osteomyelitis Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 208000007913 Pituitary Neoplasms Diseases 0.000 claims description 2
- 201000005746 Pituitary adenoma Diseases 0.000 claims description 2
- 206010061538 Pituitary tumour benign Diseases 0.000 claims description 2
- 206010050899 Porcelain gallbladder Diseases 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 2
- 208000006311 Pyoderma Diseases 0.000 claims description 2
- 206010037732 Queyrat erythroplasia Diseases 0.000 claims description 2
- 206010038074 Rectal polyp Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 206010038933 Retinopathy of prematurity Diseases 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 206010040943 Skin Ulcer Diseases 0.000 claims description 2
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims description 2
- 208000033781 Thyroid carcinoma Diseases 0.000 claims description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 208000000208 Wet Macular Degeneration Diseases 0.000 claims description 2
- 208000008919 achondroplasia Diseases 0.000 claims description 2
- 208000009621 actinic keratosis Diseases 0.000 claims description 2
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 2
- 230000022972 amelogenesis Effects 0.000 claims description 2
- 210000001691 amnion Anatomy 0.000 claims description 2
- 208000007502 anemia Diseases 0.000 claims description 2
- 206010006060 bowenoid papulosis Diseases 0.000 claims description 2
- 210000004556 brain Anatomy 0.000 claims description 2
- 208000011803 breast fibrocystic disease Diseases 0.000 claims description 2
- 206010006475 bronchopulmonary dysplasia Diseases 0.000 claims description 2
- 230000002490 cerebral effect Effects 0.000 claims description 2
- 210000003679 cervix uteri Anatomy 0.000 claims description 2
- 208000037976 chronic inflammation Diseases 0.000 claims description 2
- 208000037893 chronic inflammatory disorder Diseases 0.000 claims description 2
- 208000028715 ductal breast carcinoma in situ Diseases 0.000 claims description 2
- 201000007273 ductal carcinoma in situ Diseases 0.000 claims description 2
- 208000031068 ectodermal dysplasia syndrome Diseases 0.000 claims description 2
- 201000011523 endocrine gland cancer Diseases 0.000 claims description 2
- 201000003914 endometrial carcinoma Diseases 0.000 claims description 2
- 201000006828 endometrial hyperplasia Diseases 0.000 claims description 2
- 208000019993 erythroplakia Diseases 0.000 claims description 2
- 208000030503 familial ossifying fibroma Diseases 0.000 claims description 2
- 201000010103 fibrous dysplasia Diseases 0.000 claims description 2
- 230000003890 fistula Effects 0.000 claims description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 2
- 201000007116 gestational trophoblastic neoplasm Diseases 0.000 claims description 2
- 201000011066 hemangioma Diseases 0.000 claims description 2
- 208000014951 hematologic disease Diseases 0.000 claims description 2
- 208000014845 hemimelia Diseases 0.000 claims description 2
- 208000017819 hyperplastic polyp Diseases 0.000 claims description 2
- 238000011065 in-situ storage Methods 0.000 claims description 2
- 201000001371 inclusion conjunctivitis Diseases 0.000 claims description 2
- 230000000968 intestinal effect Effects 0.000 claims description 2
- 231100001023 lymphopenia Toxicity 0.000 claims description 2
- 230000003211 malignant effect Effects 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 206010027191 meningioma Diseases 0.000 claims description 2
- 210000001872 metatarsal bone Anatomy 0.000 claims description 2
- 210000002200 mouth mucosa Anatomy 0.000 claims description 2
- 206010028197 multiple epiphyseal dysplasia Diseases 0.000 claims description 2
- 206010028537 myelofibrosis Diseases 0.000 claims description 2
- 210000001087 myotubule Anatomy 0.000 claims description 2
- 208000012108 neoplastic polyp Diseases 0.000 claims description 2
- 201000003142 neovascular glaucoma Diseases 0.000 claims description 2
- 230000001537 neural effect Effects 0.000 claims description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 2
- 201000008968 osteosarcoma Diseases 0.000 claims description 2
- 208000003154 papilloma Diseases 0.000 claims description 2
- 208000029211 papillomatosis Diseases 0.000 claims description 2
- 201000004215 penis carcinoma in situ Diseases 0.000 claims description 2
- 208000021310 pituitary gland adenoma Diseases 0.000 claims description 2
- 208000022075 polyp of rectum Diseases 0.000 claims description 2
- 208000003476 primary myelofibrosis Diseases 0.000 claims description 2
- 208000005631 pseudoachondroplasia Diseases 0.000 claims description 2
- 201000010174 renal carcinoma Diseases 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 210000000145 septum pellucidum Anatomy 0.000 claims description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 2
- 210000002784 stomach Anatomy 0.000 claims description 2
- 208000011580 syndromic disease Diseases 0.000 claims description 2
- 210000000115 thoracic cavity Anatomy 0.000 claims description 2
- 201000005990 thymic dysplasia Diseases 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 208000013077 thyroid gland carcinoma Diseases 0.000 claims description 2
- 206010044325 trachoma Diseases 0.000 claims description 2
- 206010044412 transitional cell carcinoma Diseases 0.000 claims description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 201000006669 vulvar dystrophy Diseases 0.000 claims description 2
- 210000000707 wrist Anatomy 0.000 claims description 2
- 208000001139 Cherubism Diseases 0.000 claims 1
- 208000030649 Orofaciodigital Syndromes Diseases 0.000 claims 1
- 206010072610 Skeletal dysplasia Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 27
- 238000000034 method Methods 0.000 description 20
- -1 SF64 Chemical class 0.000 description 18
- 238000003384 imaging method Methods 0.000 description 17
- 210000001519 tissue Anatomy 0.000 description 17
- 102000005962 receptors Human genes 0.000 description 14
- 108020003175 receptors Proteins 0.000 description 14
- 239000000427 antigen Substances 0.000 description 12
- 102000036639 antigens Human genes 0.000 description 12
- 108091007433 antigens Proteins 0.000 description 12
- 230000035945 sensitivity Effects 0.000 description 12
- 125000000217 alkyl group Chemical group 0.000 description 11
- 210000004204 blood vessel Anatomy 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 210000003038 endothelium Anatomy 0.000 description 10
- 238000009607 mammography Methods 0.000 description 10
- 239000000463 material Substances 0.000 description 10
- 210000000481 breast Anatomy 0.000 description 9
- 239000002872 contrast media Substances 0.000 description 9
- 235000018102 proteins Nutrition 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- MOFVSTNWEDAEEK-UHFFFAOYSA-M indocyanine green Chemical compound [Na+].[O-]S(=O)(=O)CCCCN1C2=CC=C3C=CC=CC3=C2C(C)(C)C1=CC=CC=CC=CC1=[N+](CCCCS([O-])(=O)=O)C2=CC=C(C=CC=C3)C3=C2C1(C)C MOFVSTNWEDAEEK-UHFFFAOYSA-M 0.000 description 8
- 229960004657 indocyanine green Drugs 0.000 description 8
- 125000004964 sulfoalkyl group Chemical group 0.000 description 8
- 210000004881 tumor cell Anatomy 0.000 description 8
- 239000003814 drug Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 230000014509 gene expression Effects 0.000 description 7
- 208000003788 Neoplasm Micrometastasis Diseases 0.000 description 6
- 150000001721 carbon Chemical group 0.000 description 6
- 229910052799 carbon Inorganic materials 0.000 description 6
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical class C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 6
- 108091008605 VEGF receptors Proteins 0.000 description 5
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 5
- 230000002357 endometrial effect Effects 0.000 description 5
- 238000010253 intravenous injection Methods 0.000 description 5
- 238000006862 quantum yield reaction Methods 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 102000016359 Fibronectins Human genes 0.000 description 4
- 108010067306 Fibronectins Proteins 0.000 description 4
- 102100040578 G antigen 7 Human genes 0.000 description 4
- 108010051696 Growth Hormone Proteins 0.000 description 4
- 101000893968 Homo sapiens G antigen 7 Proteins 0.000 description 4
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 101800001814 Neurotensin Proteins 0.000 description 4
- 102100038803 Somatotropin Human genes 0.000 description 4
- 108010003205 Vasoactive Intestinal Peptide Proteins 0.000 description 4
- 102400000015 Vasoactive intestinal peptide Human genes 0.000 description 4
- 150000001413 amino acids Chemical group 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- DNDCVAGJPBKION-DOPDSADYSA-N bombesin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1NC2=CC=CC=C2C=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1NC(=O)CC1)C(C)C)C1=CN=CN1 DNDCVAGJPBKION-DOPDSADYSA-N 0.000 description 4
- 239000000470 constituent Substances 0.000 description 4
- 210000003725 endotheliocyte Anatomy 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 239000000122 growth hormone Substances 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 208000030776 invasive breast carcinoma Diseases 0.000 description 4
- VBUWHHLIZKOSMS-RIWXPGAOSA-N invicorp Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 VBUWHHLIZKOSMS-RIWXPGAOSA-N 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 210000002381 plasma Anatomy 0.000 description 4
- 230000005855 radiation Effects 0.000 description 4
- 238000002601 radiography Methods 0.000 description 4
- 159000000000 sodium salts Chemical class 0.000 description 4
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 241000699660 Mus musculus Species 0.000 description 3
- 108010013381 Porins Proteins 0.000 description 3
- 102000017033 Porins Human genes 0.000 description 3
- 239000012190 activator Substances 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 239000002870 angiogenesis inducing agent Substances 0.000 description 3
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 3
- 239000004037 angiogenesis inhibitor Substances 0.000 description 3
- SIKJAQJRHWYJAI-UHFFFAOYSA-N benzopyrrole Natural products C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000006735 deficit Effects 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- USKZHEQYENVSMH-UHFFFAOYSA-N hepta-1,3,5-triene Chemical compound CC=CC=CC=C USKZHEQYENVSMH-UHFFFAOYSA-N 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 238000011503 in vivo imaging Methods 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 238000011580 nude mouse model Methods 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- SSOORFWOBGFTHL-OTEJMHTDSA-N (4S)-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-5-carbamimidamido-1-[[(2S)-5-carbamimidamido-1-[[(1S)-4-carbamimidamido-1-carboxybutyl]amino]-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-[[(2S)-2-[[(2S)-2-[[(2S)-2,6-diaminohexanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-5-oxopentanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O SSOORFWOBGFTHL-OTEJMHTDSA-N 0.000 description 2
- 102100030310 5,6-dihydroxyindole-2-carboxylic acid oxidase Human genes 0.000 description 2
- 101710163881 5,6-dihydroxyindole-2-carboxylic acid oxidase Proteins 0.000 description 2
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 2
- 102100021305 Acyl-CoA:lysophosphatidylglycerol acyltransferase 1 Human genes 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 102000052587 Anaphase-Promoting Complex-Cyclosome Apc3 Subunit Human genes 0.000 description 2
- 108700004606 Anaphase-Promoting Complex-Cyclosome Apc3 Subunit Proteins 0.000 description 2
- 102100035526 B melanoma antigen 1 Human genes 0.000 description 2
- 235000018906 Bauhinia malabarica Nutrition 0.000 description 2
- 244000300022 Bauhinia malabarica Species 0.000 description 2
- 102000015735 Beta-catenin Human genes 0.000 description 2
- 108060000903 Beta-catenin Proteins 0.000 description 2
- 102000013585 Bombesin Human genes 0.000 description 2
- 108010051479 Bombesin Proteins 0.000 description 2
- 101150108242 CDC27 gene Proteins 0.000 description 2
- 241000282836 Camelus dromedarius Species 0.000 description 2
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 description 2
- 102100024423 Carbonic anhydrase 9 Human genes 0.000 description 2
- 102000004091 Caspase-8 Human genes 0.000 description 2
- 108090000538 Caspase-8 Proteins 0.000 description 2
- 108010031896 Cell Cycle Proteins Proteins 0.000 description 2
- 102000005483 Cell Cycle Proteins Human genes 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- 102100040606 Dermatan-sulfate epimerase Human genes 0.000 description 2
- 101710127030 Dermatan-sulfate epimerase Proteins 0.000 description 2
- 101100216227 Dictyostelium discoideum anapc3 gene Proteins 0.000 description 2
- 101150029707 ERBB2 gene Proteins 0.000 description 2
- 102100037241 Endoglin Human genes 0.000 description 2
- 102100028075 Fibroblast growth factor 6 Human genes 0.000 description 2
- 108090000382 Fibroblast growth factor 6 Proteins 0.000 description 2
- 102100039717 G antigen 1 Human genes 0.000 description 2
- 102100039699 G antigen 4 Human genes 0.000 description 2
- 102100039698 G antigen 5 Human genes 0.000 description 2
- 101710092267 G antigen 5 Proteins 0.000 description 2
- 102100039713 G antigen 6 Human genes 0.000 description 2
- 101710092269 G antigen 6 Proteins 0.000 description 2
- 102000040452 GAGE family Human genes 0.000 description 2
- 108091072337 GAGE family Proteins 0.000 description 2
- 102000009465 Growth Factor Receptors Human genes 0.000 description 2
- 108010009202 Growth Factor Receptors Proteins 0.000 description 2
- 229920002971 Heparan sulfate Polymers 0.000 description 2
- 102100028721 Hermansky-Pudlak syndrome 5 protein Human genes 0.000 description 2
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 2
- 101001042227 Homo sapiens Acyl-CoA:lysophosphatidylglycerol acyltransferase 1 Proteins 0.000 description 2
- 101000874316 Homo sapiens B melanoma antigen 1 Proteins 0.000 description 2
- 101100165850 Homo sapiens CA9 gene Proteins 0.000 description 2
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 description 2
- 101000954709 Homo sapiens Doublecortin domain-containing protein 2 Proteins 0.000 description 2
- 101001024566 Homo sapiens Ecto-ADP-ribosyltransferase 4 Proteins 0.000 description 2
- 101000886137 Homo sapiens G antigen 1 Proteins 0.000 description 2
- 101000886678 Homo sapiens G antigen 2D Proteins 0.000 description 2
- 101000886136 Homo sapiens G antigen 4 Proteins 0.000 description 2
- 101000985516 Homo sapiens Hermansky-Pudlak syndrome 5 protein Proteins 0.000 description 2
- 101000614481 Homo sapiens Kidney-associated antigen 1 Proteins 0.000 description 2
- 101001051093 Homo sapiens Low-density lipoprotein receptor Proteins 0.000 description 2
- 101001134060 Homo sapiens Melanocyte-stimulating hormone receptor Proteins 0.000 description 2
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 description 2
- 101000665137 Homo sapiens Scm-like with four MBT domains protein 1 Proteins 0.000 description 2
- 101000648075 Homo sapiens Trafficking protein particle complex subunit 1 Proteins 0.000 description 2
- 101000813738 Homo sapiens Transcription factor ETV6 Proteins 0.000 description 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 2
- 241000701806 Human papillomavirus Species 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- 108090000862 Ion Channels Proteins 0.000 description 2
- 102000004310 Ion Channels Human genes 0.000 description 2
- 108700042652 LMP-2 Proteins 0.000 description 2
- 101710192602 Latent membrane protein 1 Proteins 0.000 description 2
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 description 2
- 108010010995 MART-1 Antigen Proteins 0.000 description 2
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 2
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 2
- 102100034216 Melanocyte-stimulating hormone receptor Human genes 0.000 description 2
- 101150058357 Muc2 gene Proteins 0.000 description 2
- 101100346932 Mus musculus Muc1 gene Proteins 0.000 description 2
- 102000003505 Myosin Human genes 0.000 description 2
- 108060008487 Myosin Proteins 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 238000011786 NMRI nude mouse Methods 0.000 description 2
- 206010029113 Neovascularisation Diseases 0.000 description 2
- 102400000064 Neuropeptide Y Human genes 0.000 description 2
- 101800003845 Neuropeptide Y Proteins 0.000 description 2
- 102400001103 Neurotensin Human genes 0.000 description 2
- 102000036673 PRAME Human genes 0.000 description 2
- 108060006580 PRAME Proteins 0.000 description 2
- 102100034640 PWWP domain-containing DNA repair factor 3A Human genes 0.000 description 2
- 108050007154 PWWP domain-containing DNA repair factor 3A Proteins 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 102000013566 Plasminogen Human genes 0.000 description 2
- 108010051456 Plasminogen Proteins 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 102100022491 RNA-binding protein NOB1 Human genes 0.000 description 2
- 102100038689 Scm-like with four MBT domains protein 1 Human genes 0.000 description 2
- 101710173693 Short transient receptor potential channel 1 Proteins 0.000 description 2
- 102000013275 Somatomedins Human genes 0.000 description 2
- 102100035748 Squamous cell carcinoma antigen recognized by T-cells 3 Human genes 0.000 description 2
- 101710185775 Squamous cell carcinoma antigen recognized by T-cells 3 Proteins 0.000 description 2
- 102100025256 Trafficking protein particle complex subunit 1 Human genes 0.000 description 2
- 102100039580 Transcription factor ETV6 Human genes 0.000 description 2
- 102000016715 Transforming Growth Factor beta Receptors Human genes 0.000 description 2
- LVTKHGUGBGNBPL-UHFFFAOYSA-N Trp-P-1 Chemical compound N1C2=CC=CC=C2C2=C1C(C)=C(N)N=C2C LVTKHGUGBGNBPL-UHFFFAOYSA-N 0.000 description 2
- 102000003425 Tyrosinase Human genes 0.000 description 2
- 108060008724 Tyrosinase Proteins 0.000 description 2
- 102100027244 U4/U6.U5 tri-snRNP-associated protein 1 Human genes 0.000 description 2
- 101710155955 U4/U6.U5 tri-snRNP-associated protein 1 Proteins 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 102000040856 WT1 Human genes 0.000 description 2
- 108700020467 WT1 Proteins 0.000 description 2
- 101150084041 WT1 gene Proteins 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium group Chemical group [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 201000010989 colorectal carcinoma Diseases 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 210000005168 endometrial cell Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 2
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 210000000713 mesentery Anatomy 0.000 description 2
- PCJGZPGTCUMMOT-ISULXFBGSA-N neurotensin Chemical class C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 PCJGZPGTCUMMOT-ISULXFBGSA-N 0.000 description 2
- 150000002892 organic cations Chemical group 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 230000008521 reorganization Effects 0.000 description 2
- 238000003375 selectivity assay Methods 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 102100027398 A disintegrin and metalloproteinase with thrombospondin motifs 1 Human genes 0.000 description 1
- 102100032635 A disintegrin and metalloproteinase with thrombospondin motifs 8 Human genes 0.000 description 1
- 108091005666 ADAMTS8 Proteins 0.000 description 1
- 102100034594 Angiopoietin-1 Human genes 0.000 description 1
- 102100034608 Angiopoietin-2 Human genes 0.000 description 1
- 102400000068 Angiostatin Human genes 0.000 description 1
- 108010079709 Angiostatins Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 108010081589 Becaplermin Proteins 0.000 description 1
- 101100208237 Bos taurus THBS2 gene Proteins 0.000 description 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 description 1
- 101710098275 C-X-C motif chemokine 10 Proteins 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000009458 Carcinoma in Situ Diseases 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 102100031186 Chromogranin-A Human genes 0.000 description 1
- 102100026735 Coagulation factor VIII Human genes 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 108010036395 Endoglin Proteins 0.000 description 1
- 101150021185 FGF gene Proteins 0.000 description 1
- 108091008794 FGF receptors Proteins 0.000 description 1
- 206010067141 Faciodigitogenital dysplasia Diseases 0.000 description 1
- 241000214925 Gonatas Species 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 206010050469 Holt-Oram syndrome Diseases 0.000 description 1
- 101000936405 Homo sapiens A disintegrin and metalloproteinase with thrombospondin motifs 1 Proteins 0.000 description 1
- 101000924552 Homo sapiens Angiopoietin-1 Proteins 0.000 description 1
- 101000924533 Homo sapiens Angiopoietin-2 Proteins 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 1
- 101000898034 Homo sapiens Hepatocyte growth factor Proteins 0.000 description 1
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 description 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 1
- 101000868152 Homo sapiens Son of sevenless homolog 1 Proteins 0.000 description 1
- 101000830596 Homo sapiens Tumor necrosis factor ligand superfamily member 15 Proteins 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100026720 Interferon beta Human genes 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 102000003810 Interleukin-18 Human genes 0.000 description 1
- 108090000171 Interleukin-18 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 229940124761 MMP inhibitor Drugs 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 102000004264 Osteopontin Human genes 0.000 description 1
- 108010081689 Osteopontin Proteins 0.000 description 1
- 108010064719 Oxyhemoglobins Proteins 0.000 description 1
- 101800000990 PEX Proteins 0.000 description 1
- 235000010678 Paulownia tomentosa Nutrition 0.000 description 1
- 240000002834 Paulownia tomentosa Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102100035153 Phosphate-regulating neutral endopeptidase PHEX Human genes 0.000 description 1
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 description 1
- 102100039418 Plasminogen activator inhibitor 1 Human genes 0.000 description 1
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000006994 Precancerous Conditions Diseases 0.000 description 1
- 102000011195 Profilin Human genes 0.000 description 1
- 108050001408 Profilin Proteins 0.000 description 1
- 102100024819 Prolactin Human genes 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 1
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108091005735 TGF-beta receptors Proteins 0.000 description 1
- 108010046722 Thrombospondin 1 Proteins 0.000 description 1
- 108010092867 Transforming Growth Factor beta Receptors Proteins 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 102100024587 Tumor necrosis factor ligand superfamily member 15 Human genes 0.000 description 1
- 102000008790 VE-cadherin Human genes 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 1
- 229940120638 avastin Drugs 0.000 description 1
- DCBDOYDVQJVXOH-UHFFFAOYSA-N azane;1h-indole Chemical compound N.C1=CC=C2NC=CC2=C1 DCBDOYDVQJVXOH-UHFFFAOYSA-N 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 108010018828 cadherin 5 Proteins 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001767 cationic compounds Chemical group 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000005482 chemotactic factor Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 239000000994 contrast dye Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000002059 diagnostic imaging Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 230000009088 enzymatic function Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 108060002566 ephrin Proteins 0.000 description 1
- 102000012803 ephrin Human genes 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 102000052178 fibroblast growth factor receptor activity proteins Human genes 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000029427 heart-hand syndrome Diseases 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 150000002433 hydrophilic molecules Chemical class 0.000 description 1
- 230000037315 hyperhidrosis Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910001411 inorganic cation Chemical group 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000032630 lymph circulation Effects 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000000329 lymphopenic effect Effects 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000013178 mathematical model Methods 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 description 1
- 210000004088 microvessel Anatomy 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 1
- 208000025189 neoplasm of testis Diseases 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 238000011369 optimal treatment Methods 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 125000001151 peptidyl group Chemical group 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229940097325 prolactin Drugs 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 208000023958 prostate neoplasm Diseases 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000011309 routine diagnosis Methods 0.000 description 1
- 201000008261 skin carcinoma Diseases 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000008354 sodium chloride injection Substances 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 125000004646 sulfenyl group Chemical group S(*)* 0.000 description 1
- 238000001931 thermography Methods 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 208000024719 uterine cervix neoplasm Diseases 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 108010060757 vasostatin Proteins 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0032—Methine dyes, e.g. cyanine dyes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0032—Methine dyes, e.g. cyanine dyes
- A61K49/0034—Indocyanine green, i.e. ICG, cardiogreen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0058—Antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明涉及菁染料SF64在给药小于5mg/kg体重时用于诊断增生性疾病的用途。
Description
本发明涉及菁染料,特别是SF64、5-29、5-36和/或5-41在少于0.1mg/kg体重的给药后,用于诊断增生性疾病,特别是肿瘤疾病的用途。
发明背景
癌症是美国人中引起死亡的第二大原因,在美国每四例死亡中就有一例是癌症引起的。在2004年,超过560,000名美国人,或者每天有超过1,500人将死于癌症。自1990年以来,已经诊断出超过1800万新癌症病例,仅在2004年就将诊断约140万新病例。此估算还不包括预期将在今年诊断的侵袭前癌症或者大于100万非黑素瘤皮肤癌的病例。癌症的经济成本是极高的。根据美国国立卫生研究院的信息,2003年美国的癌症花费超过1890亿美元。该金额包括超过640亿美元的直接医学花费和超过1250亿美元的生产力损失。通过癌症的早期诊断,可充分减少新的癌症死亡数字。因此,通过在最可治疗的早期发现癌症,癌症筛查,特别是乳腺癌、子宫颈癌和结肠直肠癌的筛查实验能够显著减少该疾病的死亡数字。通过检测可治疗的癌前状态,乳腺癌、子宫颈癌和结肠直肠癌的筛查实验可实际地防止这些癌症的发生。
理想的筛查方法是灵敏且特异的,能被快速执行,是非侵入的,廉价且无副作用或仅具有可忽略的副作用。对于例如乳房肿瘤的筛查,目前确立的筛查标准包括乳房组织的X射线成像,该操作也被称为乳房X线照相术。其他方法包括磁共振成像、超声波检查法和温度记录法。到目前为止,最广泛实施的筛查方法为乳房X线照相术,其具有高度特异性(约80%),然而,其灵敏度主要取决于放射学家对成像数据的解释。乳房X线照相术的空间分辨率低且所检测的肿瘤通常具有1cm或更大的尺寸。但是,乳房X线照相术伴有射线照射的显著和累积的危险,特别在绝经前的妇女中,她们与老年妇女相比,具有更致密的乳房组织并需要更高的辐射剂量以获得足够的灵敏度。乳房X线照相术还被批评在操作期间有力地控制乳房,这可能会促进肿瘤细胞的散布。在过去,磁共振成像(MRI)已经被愈加使用,特别是在已经用不同方法识别肿瘤之后。MRI成像与基于X射线的成像技术如乳房X线照相术相比,由于其高度的空间分辨率,其具有非常优越的灵敏度,但是,它是特异性较低的(特异性范围从37%至97%,且对以前没有诊断出乳腺癌的妇女的预测值小于2%),昂贵得多并且耗时,因此,较不适合患者的普筛。
近来,出现了在近红外(NIR)中被称为扩散光X线体层摄影(DOT)的另外的方法,作为一种新的成像方法在许多医学成像应用中具有高度潜力。该技术具有产生本征和非本征的吸收和散射的定量图像的能力(Arridge,S.R.(1995)Appl.Opt.34:7395-7409和Gonatas,C.P.等人(1995)Phys.Rev.E.52:4361-4365)。Ntziachristos,V.等人(2000)Proc.Nat.Aca.ScL U.S.A.97:2767-2772)描述了吲哚菁绿(ICG)在体内在人类乳房的光学成像期间用于造影增强的用途。因为组织在700至850nm光谱区的低吸收,大器官如乳房的光学成像通常是可行的。事实上,从二十世纪二十年代后期,光已被作为通过透照法针对乳腺癌的诊断工具来研究。然而,透照法具有低的空间分辨率,且几乎不提供检测的损伤的光谱量化。因此,透照法不能获得要被临床使用的足够的灵敏度和特异性。组织中光传播数学模型的巨大改进结合技术进步现已使得能够应用X线体层摄影原理以扩散光进行成像。扩散光X线体层摄影术已经显著改善了用光定位和量化组织结构的能力。此外,所述方法应用非离子化辐射,使用相对低成本的设备,其使它适于乳腺癌或光线可达到的其他癌症的普筛。荧光染料如吲哚菁绿(ICG,其为NIR中的吸收剂和荧光团)已被用作造影剂。对于使用FCG作为造影剂的DOT,已报道在0.25mg/kg体重的浓度时,能检测1cm或更大尺寸的乳腺导管癌。能被用于近红外荧光造影成像的其他荧光造影剂描述于例如EP 1 113 822 A1和KaiEP 1 113 822 A1以及Kai Licha等人((2000)Photochemistry andPhotobiology 72:392-398)中。
对于重复筛查中执行的任何成像方法,期望它们具有尽可能小的副作用。如果所述成像技术要求给药物质如造影剂,则期望仅给药少量的该物质,以避免潜在的有害副作用和药物蓄积,其可能在重复给药时发生。因此,现有技术中需要确定这样的造影剂,其能以小量给药且仍将为DOT的常规筛查应用提供期望的特异性和灵敏度。
发明详述
在下文详述本发明前,应理解本发明不限于本文描述的特定方法学、方案、细胞系、载体和试剂,因为这些可以变化。还应理解,本文所用的术语仅为描述特定的实施方案,且非意在限制本发明的范围,本发明的范围将仅由所附的权利要求进行限制。除非另有说明,本文所用的所有技术和科学术语具有与本领域普通技术人员通常所理解的相同的含义。
优选地,本文所用术语如“A multilingual glossary of bio-technological terms:(IUPAC Recommendations)”,Leuenberger,H.G.W,Nagel,B.和KM,H.eds.(1995),Helvetica Chimica Acta,CH-4010 Basel,Switzerland)中所述定义。
贯穿本说明书和接着的权利要求,除非上下文另有要求,单词“包括”,及其变体如“包含”将理解为意指包括所述的整数或步骤或者整数或步骤的组,但不排除任何其他整数或步骤或者整数或步骤的组。
贯穿本说明书的正文引用了一些文件。无论在上文或下文中,本文引用的每个文件(包括所有专利、专利申请、科学出版物、制造商的说明书、指示等)都以其全文引入本文作为参考。本文不应被解释为承认本发明因为在先的发明而无资格先于这样的公开。
必须注意,除非上下文另有明确说明,用于本文和所附权利要求中的单数形式“一”和“所述”包括复数对象。因此,例如:提及“一种试剂”包括一种或多种这样的不同试剂,提及“所述方法”包括提及本领域普通技术人员已知的等同步骤和方法,其能被本文描述的方法修正或代替。
已知现有技术中的上述需要,本发明人现已惊讶地发现先前已知的式(I)的化合物及其药学可接受的盐,例如Na、K、Ca、Mg2+等:
其中L1至L7为相同或不同的,且各自为取代或未取代的甲烷,或者L3和L5共同形成五元或六元环,L4为被具有1至4个,例如1、2、3或4个碳原子的烷基取代的甲烷,R1和R2为具有1至5个,例如1、2、3、4或5个碳原子并被磺酸基取代的低级烷基或任选取代的芳基或杂芳基,R3至R10为相同或不同的,且各自为氢原子、磺酸基、羧基、羟基、烷基(磺烷基)氨基、二(磺烷基)氨基、磺烷氧基、(磺烷基)磺酰基或(磺烷基)氨基磺酰基,且X和Y为相同或不同的,且各自为式(II)的基团,
其中R11和R12为具有1至5个,例如1、2、3、4或5个碳原子的未取代的低级烷基。这些化合物以每kg体重的用量提供具有足以用于增生性疾病的常规筛查的特异性和灵敏度的信号,其每kg体重的用量显著低于现有技术中用于获得足够的特异性和灵敏度的每kg体重的用量。
在本发明的上下文中使用的特别优选的化合物是一种或多种具有式(III)至(VI)的结构的化合物,
还已知其名为SF64、5-29、5-36和5-41,其以每kg体重的用量提供具有足以用于增生性疾病的常规筛查的特异性和灵敏度的信号,其每kg体重的用量显著低于现有技术中用于获得足够的特异性和灵敏度的每kg体重的用量。因此,本发明可用的化合物,特别是SF64、5-29、5-36和5-41能够令人惊讶地以非常小的量给药,从而具有潜在的低毒副作用。此外,在此低浓度下可检测的肿瘤直径小到3mm,这显著小于以前使用其他菁染料如ICG所检测的肿瘤,后者的检测限是尺寸为1cm的肿瘤,即:可与乳房X线照相术比较。检测小到3mm的肿瘤的能力表示比能够检测下至10mm的尺寸的肿瘤的能力的显著进步,并具有对于被诊断患者的长期存活的巨大暗示。直径为1cm或更大的肿瘤已吸引内皮细胞形成新的毛细血管,即已被新血管化(neo-vasularize),且通常已经向血液或淋巴循环中释放了肿瘤细胞。但是,直径为3mm或更小的肿瘤通常没有血管化,且由于缺乏营养素,已经停止进一步生长。由于所述肿瘤的血管化是进一步生长的必要条件,所以这些肿瘤只有在形成吸引内皮细胞的能力时才会发展。因此,如果所述肿瘤能在更少可能已经扩散到身体和/或已经吸引内皮细胞形成新毛细血管的尺寸时被检测到,那么防止肿瘤发展成威胁生命的疾病的机会将高得多。
因此,本发明的第一方面是式(I)的化合物或其药学可接受的盐在制备用于检测增生性疾病的诊断组合物中的用途,其中所述诊断组合物包含每次诊断施用小于0.5并大于0.001mg/kg体重的量的所述化合物,
其中L1至L7为相同或不同的且各自为取代或未取代的次甲基,L4为被具有1至4个,例如1、2、3或4个碳原子的烷基取代的甲烷,R1和R2为具有1至5个,例如1、2、3、4或5个碳原子并被磺酸基取代的低级烷基,R3至R10为相同或不同的且各自为氢原子、磺酸基、羧基、羟基、烷基(磺烷基)氨基、二(磺烷基)氨基、磺烷氧基、(磺烷基)磺酰基或(磺烷基)氨基磺酰基,且X和Y为相同或不同的,且各自为式(II)的基团,
其中R11和R12为具有1至5个,例如1、2、3、4、或5个碳原子的未取代的低级烷基。
在本发明的上下文中使用的特别优选的化合物是用于制备检测增生性疾病的诊断组合物的一种或多种具有式(III)至(VI)的结构的化合物或其药学可接受的盐,
其中所述诊断组合物包含每次诊断施用小于0.5并大于0.001mg/kg体重的量的所述化合物。
本发明可用的亲水化合物,特别是菁染料SF64、5-29、5-36和5-41作为造影剂的能力部分地由氧合血红蛋白和二氧合血红蛋白浓度、血液氧化剂饱和度、摄取进组织中的造影剂和器官浓度决定,但是,通过将本发明可用的化合物,特别是SF64、5-29、5-36和5-41偶联到靶向化合物,可能增加其特异性和/或灵敏度,所述靶向化合物与优先地或只存在于正在增生的细胞和组织上或在正在增生的细胞和组织附近的结构特异地结合。这些结构中的有些直接与正在增生的细胞有关,或者与增生性组织附近的细胞有关。前者是在正在增生的细胞中被改变或过度表达的结构,如例如生长因子受体,如促生长素抑释素受体或表皮生长因子受体(FGFR)。至今已经识别了大量这样的结构,包括但不限于生长因子受体、G-蛋白偶联受体、孔蛋白(pore protein)、离子通道、药物流出泵、生长因子的辅助结合位点、硫酸乙酰肝素、膜结合蛋白酶、黏附分子、T细胞受体及选择蛋白,特别是EGF、TGF、CEA、Lewis Y、CD20、CD33或CD38。能被靶向的其他结构为T细胞定义的癌症相关的抗原,其属于突变的或重组的细胞基因的独特的基因产物,特别是细胞周期蛋白依赖性激酶4(CDK4)、p15Ink4b、p53、AFP、β-连环蛋白、胱天蛋白酶8、p53、p21Ras突变、Bcr-ab1融合产物、MUM-1、MUM-2、MUM-3、ELF2M、HSP70-2M、HST-2、KIAA0205、RAGE、肌球蛋白/m、707-AP、CDC27/m、ETV6/AML、TEL/Am11、Dekcain、LDLR/FUT、Pm1-RARα、TEL/AMLI;癌-睾丸(CT)抗原,特别是NY-ESO-1、MAGE家族的成员(MAGE-A1、MAGE-A2、MAGE-A3、MAGE-A4、MAGE-A6、MAGE-10、MAGE-12)、BAGE、DAM-6、DAM-10、GAGE家族的成员(GAGE-1、GAGE-2、GAGE-3、GAGE-4、GAGE-5、GAGE-6、GAGE-7B、GAGE-8)、NA-88A、CAG-3、RCC相关的抗原G250;肿瘤病毒抗原,特别是源自人乳头状瘤病毒(HPV)的E6或E7癌蛋白、EB病毒EBNA2-6、LMP-1、LMP-2;过表达的或组织特异性的分化抗原,特别是gp77、gp100、MART-1/Melan-A、p53、酪氨酸酶、酪氨酸酶相关蛋白(TRP-1和TPR-2)、PSA、PSM、MC1R;广泛表达的抗原,特别是ART4、CAMEL、CEA、CypB、HER2/neu、hTERT、hTRT、ICE、Muc1、Muc2、PRAME RU1、RU2、SART-1、SART-2、SART-3和WT1。
已知正在增生的细胞,特别是肿瘤细胞产生可扩散的因子,其吸引内皮细胞并刺激它们生长。因此,肿瘤是体内观察到新血管化的少数区域之一。从而,正在增生的肿瘤内皮及其相关结构已被用于将药物特异性地靶向至肿瘤部位。与血管发生相关的分子结构综述于例如WO96/01653,Alessi P.等人(2004)以及Nanda,H.和Saint-Croix(2004)中。形成增生性组织的细胞同时表达血管发生因子和抗血管发生因子,只要血管发生抑制剂抵抗血管发生因子的作用,其就导致血管发生的抑制。一旦血管发生因子的作用占优势,它们就导致引发血管发生。因此,在调节血管发生中所涉及的两种结构,即血管发生激活剂和抑制剂都可被本发明的靶向化合物结合。血管发生激活剂包括但不限于如下分子结构,例如ED-B纤连蛋白(ED-BF)、内皮联蛋白(endogline)(CD105)(Burrows,F.J.等人(1997)Clin.Cancer Res.1:1623-1634)、VEGF家族成员、血管内皮生长因子(VEGFR)、NRP-1、Ang1、Thie2、PDGF-bb及受体、TGF-β1、TGF-β受体、FGF、HGF、MCP-1、整合体(αvβ3、αvβ5、α5β1)、VE-钙粘着蛋白、PICAM(CD31)、ephrins、纤溶酶原激活物、MMPs PAI-1、NOS、COX-2、A733、趋化因子或Id1/Id3。血管发生抑制剂包括但不限于如下分子结构,例如VGFR-1、Ang2、TSP-1、TSP-2、血管生成抑制素和相关的纤溶酶原三环域(kringles)、内皮抑制肽(胶原(XVII片段)、vasostatin、血小板因子IV、TIMPs、MMP抑制剂、PEX、METH-1、METH-2、IFN-α、IFN-β、IFN-γ、IP-10、IL-4、IL-12、IL-18、促乳素、VEGI、SPARC的片段、骨桥蛋白片段或乳腺丝酶抑制蛋白(Carmeliet,P.和Jain,R.K.(2000)Nature 407:249-257;Yancopoulos,G.D.等人(2000)Nature 407:242-248;Bergers,G.和Benjamin,L.E.(2002)Nature Reviews Cancer 3:401-410;Hendriks,M.J.C.等人(2002)NatureReviews Cancer 3:411-421)。
在一优选的实施方案中,所述靶向化合物与血管发生特异性因子ED-BF、VEGFR或内皮联蛋白(endoglin)结合。在那些中,ED-BF是特别优选的靶结构。ED-BF是纤连蛋白的剪接变体,也称为癌胚纤连蛋白,其在血管发生期间,在新生长的微血管结构中特异地形成。
与这些结构结合的成分优选为肽(具有2至50个氨基酸残基的氨基酸链)、蛋白质(具有超过50个氨基酸残基的氨基酸链)、核酸、小分子或糖。在本说明书的其他部分中,肽和蛋白质也通常被称为多肽。
优选的多肽是优先地或只在正在增生的细胞中或在正在增生的细胞附近,例如在已经血管化或正在血管化的结构中表达的结构的配体,特别是血管内皮生长因子(VEGF)、促生长素抑释素、促生长素抑释素类似物、铃蟾肽、铃蟾肽类似物、血管活性肠肽(VIP)及类似物、神经降压肽和神经降压肽类似物、神经肽Y及类似物和抗体,包括人抗体、人源化抗体和嵌合抗体;包括片段如Fv、Fab、Fab′、F(ab′)2、Fabc、Facb的抗体结合结构域;单链抗体如单链Fvs(scFvs);以及双功能抗体(diabodies)。
文献中已经描述了大量这样的抗体,包括对于ED-BF:L19和E8(参见Viti F.等人(1999)Cancer Res.59:347-352)、EP 0 344 134 B1中描述的可以从保藏在欧洲动物细胞培养物保藏中心(European Collection ofAnimal Cell Cultures,Porton Down,Salisbury,UK)的编号为88042101的杂交瘤获得的BC-1单克隆抗体或其嵌合形式或人源化形式、WO97/45544 A1中公开的具有特异性VL和VH序列的抗ED-BF的抗体、WO 99/5857 A2中公开的具有特异性VL和VH序列的抗ED-BF的抗体、WO 01/62800 A1中公开的具有特异性VL和VH序列的抗ED-BF的抗体和AP38以及AP39(Marty C等人(2001)Protein Expr.Purif.21:156-64)。在Ebbinghaus C等人(2004)Curr Pharm Des.10:1537-49中已综述了对ED-BF具有特异性的抗体。所有这些抗体或其抗体结合片段都可用作本发明优选用途中的血管发生特异性的结合成分。特别优选的抗体为L19、E8、AP38和AP39或其包含结合结构域的片段。
针对VEGF-R的抗体包括贝伐单抗(AvastinTM,由Genentech和Roche开发的rhumAb-VEGF)、抗VEGFR-1抗体mAb 6.12、全人抗VEGFR-2抗体IMC-2C6和IMC-1121、全人抗VEGFR-3mAb HF4-3C5(均属于Imclone Systems Inc.),以及KM-2550(Kyowa Hakko Kogyo CoLtd)、一种抗VEGFR-1抗体(Salgaller ML(2003)Current Opinion inMolecular Therapeutics 5(6):657-667)。针对内皮联蛋白的抗体包括:SN6h、SN6、SN6a、SN6j、P3D1、P4A4、44G4、GRE、E-9、CLE-4、RMAC8、PN-E2、MAEND3、TEC4、TEC11、A11、8E11。克隆SN6h已被广泛用于通过免疫组织化学研究内皮联蛋白在不同肿瘤实体中的表达(Wikstrm P.等人(2002)The Prostate 51:268-275;Li C.等人(2003)Br.J.Cancer 88:1424-1431;Saad R.S.等人(2004)Modern Pathol.17:197-203)。已经描述了同一SN6系列的抗体SN6、SN6a和SN6j(She X.等人(2004)Int.J.Cancer 108:251-257)。对于抗体克隆P3D1、P4A4、44G4、GRE、E-9、CLE-4、RMAC8、PN-E2、MAEND3、TEC4、TEC11,已经确定了内皮联蛋白的结合表位(Pichuantes S.等人(1997)Tissueantigens 50:265-276)。对于这些抗体和抗体克隆A11中的一些,已在人源正常组织和肿瘤组织中研究了内皮联蛋白的差异表达(Duff S.E.等人(2003)FASEB J.17:984-992)。WO 02/02614公开了其他内皮联蛋白特异性抗体,例如scFv C4。在一篇关于抗CD105的抗体的最近的出版物中,通过免疫组织化学研究了克隆8E11在乳腺癌患者中对转移危险的预测(Dales J.P.等人(2004)Br.J.Cancer 90:1216-1221)。所有这些抗体或其抗体结合片段都可用作本发明的优选的用途中的血管发生特异性结合成分。
此外,现有技术中已描述了特异性地结合至各种肿瘤细胞本身的许多抗体或其结合片段,包括但不限于G-蛋白偶联受体、孔蛋白、离子通道、药物流出泵、生长因子的辅助结合位点、硫酸乙酰肝素、膜结合蛋白酶、黏附分子、T细胞受体和选择蛋白,特别是EGF、TGF、CEA、Lewis Y、CD 20、CD 33或CD38。此外,可以使用属于突变的或重组的细胞基因的独特的基因产物的抗T细胞定义的肿瘤相关抗原的抗体或其结合片段,特别是细胞周期蛋白依赖性激酶4(CDK4)、p15Ink4b、p53、AFP、β-连环蛋白、胱天蛋白酶8、p53、p21Ras突变、Bcr-ab1融合产物、MUM-1、MUM-2、MUM-3、ELF2M、HSP70-2M、HST-2、KIAA0205、RAGE、肌球蛋白/m、707-AP、CDC27/m、ETV6/AML、TEL/Am11、Dekcain、LDLR/FUT、Pm1-RARα、TEL/AMLI;癌-睾丸(CT)抗原,特别是NY-ESO-1、MAGE家族的成员(MAGE-A1、MAGE-A2、MAGE-A3、MAGE-A4、MAGE-A6、MAGE-10、MAGE-12)、BAGE、DAM-6、DAM-10、GAGE家族的成员(GAGE-1、GAGE-2、GAGE-3、GAGE-4、GAGE-5、GAGE-6、GAGE-7B、GAGE-8)、NA-88A、CAG-3、RCC相关的抗原G250;肿瘤病毒抗原,特别是源自人乳头瘤病毒(HPV)的E6或E7癌蛋白、EB病毒EBNA2-6、LMP-1、LMP-2;过表达的或组织特异性的分化抗原,特别是gp77、gp100、MART-1/Melan-A、p53、酪氨酸酶、酪氨酸酶相关蛋白(TRP-1和TPR-2)、PSA、PSM、MC1R;广泛表达的抗原,特别是ART4、CAMEL、CEA、CypB、HER2/neu、hTERT、hTRT、ICE、Muc1、Muc2、PRAME RU1、RU2、SART-1、SART-2、SART-3和WT1。
本领域公知核酸可具有特异性结合性质,因此,所述靶向成分也可为核酸。优选地,这样的核酸包括DNA、RNA、适体和PNA,其中特别优选适体。识别特异性结合适体的方法在本领域中是公知的,且被描述于例如WO 93/24508 A1、WO 94/08050 A1、WO 95/07364 A1、WO96/27605 A1和WO 96/34875 A1中。本文特别参考这些文件中公开的方法,所述方法可用于识别如下适体,其特异性结合至正在增生的组织或正在增生的组织附近的组织,例如新形成的和/或正在增生的内皮。对于本发明的用途特别优选的靶向化合物是血管发生特异性结合适体。本发明的用途中所采用的优选适体特异性地识别ED-BF、内皮联蛋白或VEGFR。
随着小分子,即分子量低于1.000g/mol,优选地低于500g/mol的非肽基非核酸化合物的高通量筛查的出现,已经可能识别具有特定结合性质的小分子。这样的小分子同样可被用作本发明的用途中的靶向成分。优选的小分子为2,2-二苯基乙胺,其已被确定与ED-BF特异地结合(Scheuermann J.(2002)Isolation of binding molecules to the EDB domainof fibronectin,a marker of angiogenesis.Dissertation submitted to SwissFederal Inst.of Technology,Zurich)。
上述靶向化合物能通过直接的或间接的键与本发明可用的化合物,特别是SF64、5-29、5-36和/或5-41偶联。在上下文中,术语“直接的键”表示对于所述靶向化合物残基的共价键,而本文所用的术语“间接的键”表示通过共价或非共价键连接的一个或多个位于所述SF64染料和所述靶向化合物之间的另外的化学残基。这些一个或多个另外的化学残基也被称为“间隔基”。间隔基能例如在所述靶向化合物和所述SF64染料间提供空间分离。将本发明可用的化合物且特别是菁染料SF64、5-29、5-36和/或5-41偶联至上文概述的靶向化合物的一些方法是本领域已知的,这些方法通常包括将反应官能团引入所述染料,将所述染料合成为具有反应官能团的和/或在所述靶向化合物中的衍生物,其能形成共价键。这样的基团包括例如硫基(thio)、羟基、氨基或羧基。对于本发明可用的化合物且特别是SF64、5-29、5-36和/或5-41,能在吲哚基和/或吲哚杂环3位的甲基,或在位于庚三烯中部的甲基上实现偶联,或者能在庚三烯的任何碳残基上实现偶联。此外,能在连接至吲哚氮的烷基链上实现所述靶向化合物与本发明可用的化合物,特别是SF64、5-29、5-36和/或5-41之间的偶联。优选地,所述靶向化合物与吲哚3位甲基中的一个偶联,或者与庚三烯的4-甲基偶联。
术语“受体的配体”指多肽,其特异性地与细胞表面受体结合,即它们是所述受体的天然结合伙伴(partner)。所述受体及其配体之间的相互作用可能具有不同的结果,一方面可能所述配体与受体仅在例如两个细胞之间的范围发生作用,或者所述结合可能导致所述受体的构象或功能变化,其又可导致例如激活受体的酶功能,或使所述受体与细胞膜内的新的和/或不同的其他成分在胞外位点或在细胞膜的细胞质位点上缔合。关于这点,配体能对受体功能具有激动或拮抗效应。在本发明的意义中,受体配体也是被修饰的配体,其可能携带其他N-或C-端氨基酸,或者其中氨基酸已经被取代,而不会显著减少对受体的结合活性。关于这点,减少超过90%将被认为是显著的。优选地,修饰的配体显示出特异性结合的增加。这样的受体配体的例子为VEGF、促生长素抑释素及其类似物、铃蟾肽或和铃蟾肽类似物、血管活性肠肽(VIP)及类似物、神经降压肽和神经降压肽类似物、神经肽Y及其类似物。
优选地,上述根据式(I)和/或(III)至(VI)的化合物作为钠盐使用,但是除了钠盐或代替钠盐,也可能使用其他药学可接受的盐,即用一个或多个药学可接受的其他有机或无机阳离子代替分子中的一个或多个钠离子,这些阳离子包括其他碱金属离子如钾,碱土金属如镁、钙等,有机阳离子如三乙铵、三丁铵、吡啶鎓等,氨基酸如赖氨酸、精氨酸等的盐。本发明可用的化合物的特别优选的钠盐示于式(VII)中。
能够使用上文指示的量的本发明可用的化合物诊断的增生性疾病优选地选自:肿瘤、初癌状态、发育不良、化生、银屑病、银屑病关节炎、类风湿性关节炎、子宫内膜异位症和/或眼病。
优选的被诊断的增生性疾病为肿瘤。肿瘤可被进一步区分为原发性肿瘤或其转移。通常,已经转移的细胞生长得更迅速,显示出较少的贴壁依赖性,具有更高的染色体倍性,并且由于蛋白酶如胶原蛋白酶、基质金属蛋白酶等的表达,已经获得了从循环中溢出的能力。因此,肿瘤优选地在其已转移前被诊断。而原发性肿瘤形成转移的危险通常随着增加一些肿瘤的尺寸而增加,如黑素瘤通常在仅仅具有一毫米或几毫米的尺寸时就开始转移,其他肿瘤远远较不易于将肿瘤细胞早期分布到全身,如前列腺癌。本发明的用途的一个显著优点是能检测小尺寸的增生性病变,特别是原发性肿瘤。优选地,检测的增生性病变小于10mm,优选小于9mm,优选小于8mm,优选小于7mm,优选小于6mm,优选小于5mm且最优选小于4mm。
优选地,根据本发明的用途所诊断的肿瘤为胃肠道或结肠直肠道的恶性瘤(malignoma)、肝癌、胰腺癌、肾癌、膀胱癌、甲状腺癌、前列腺癌、子宫内膜癌、卵巢癌、睾丸癌、黑素瘤、口腔粘膜发育异常(dysplasticoral mucosa)、侵入性口腔癌(invasive oral cancer)、小细胞或非小细胞肺癌;乳房肿瘤,包括激素依赖性乳腺癌、激素非依赖性乳腺癌;移行细胞癌和鳞状细胞癌;神经恶性肿瘤,包括神经母细胞瘤、神经胶质瘤、星形细胞瘤、骨肉瘤、脑膜瘤;软组织肉瘤;血管瘤(hemangioama)和内分泌肿瘤,包括垂体腺瘤、嗜铬细胞瘤、副神经节瘤、包括淋巴瘤和白血病的恶性血液病,或者源自上述肿瘤中的一种的转移。特别优选的肿瘤为乳房肿瘤、子宫颈肿瘤、前列腺肿瘤、睾丸肿瘤,其中从体外或通过内窥镜检查的方式易于进入形成肿瘤的器官/组织。
根据本发明的用途可检测的初癌状态优选地选自皮肤的初癌状态,特别是光化性角化病、皮角(cutaneaous horn)、光化性唇炎、焦油角化病、砷角化病、x射线角化病、鲍恩病、鲍恩样丘疹病、恶性雀斑样痣、硬化性苔藓和粘膜红苔藓(lichen rubber mucosae);消化道的初癌状态,特别是粘膜红斑、白斑、巴雷特食管、普-文综合征、脚溃疡、过度生长的胃肥大(gastropathia hypertrophica gigantea)、边缘癌(borderlinecarcinoma)、瘤形成的肠息肉、直肠息肉、瓷胆囊;妇科的初癌状态,特别是原位导管癌(CDIS)、宫颈上皮内瘤样病变(CIN)、白斑、子宫内膜增生(III级)、外阴营养不良、外阴上皮内瘤样病变(VIN)、葡萄胎;泌尿科的初癌状态,特别是膀胱乳头状瘤病、凯拉增殖性红斑、睾丸上皮内瘤样病变(TIN)、白斑;原位癌(CIS);由慢性炎症,特别是脓皮病、骨髓炎、聚合性痤疮、寻常狼疮和瘘引起的初癌状态。
发育不良通常是癌症的预兆,其主要出现在上皮中;它是非肿瘤细胞生长的最无序形式,包括单个细胞均匀性和细胞构造取向(architectural orientation)的丧失。发育不良的细胞通常具有异常巨大的强染色的细胞核,并表现出多形性。当存在慢性刺激或炎症时,特征性地发生发育不良。可根据本发明诊断的发育不良疾病包括但不限于先天性外胚层发育不全、前颜面发育异常(anterofacial dysplasia)、窒息性胸廓发育不良、心-指发育不良(atriodigital dysplasia)、支气管肺发育不良、脑发育不良、宫颈结构不良、软骨外胚层发育不良、锁颅发育不全、先天性外胚层发育不良、颅面骨干发育不全(craniodiaphysial dysplasia)、颅腕跖骨发育不全、颅干骺发育不全(craniometaphysial dysplasia)、牙本质发育异常、骨干发育不全、外胚层发育不良、釉质发育异常、脑眼球发育不全、骺(epiphysialis)发育不全半肢畸形、多发性骨骺发育不良、点状骨骺发育不良、上皮异常增生(epithelial dysplasia)、面-指-生殖器发育不良(faciodigitogenital dysplasia)、家族性颌骨纤维性结构不全、家族性白色皱襞性发育不良(familial white folded dysplasia)、肌纤维结构不良、骨纤维性结构不良、红润色骨发育不全、遗传性肾-视网膜发育不良、多汗性外胚层发育不全、少汗性外胚层发育不全、淋巴细胞减少性(lymphopenic)胸腺发育不全、乳腺结构不良、下颌骨颜面发育不良(mandibulofacial dysplasia)、骨骺端发育不全(metaphysical dysplasia)、Mondini畸形、单骨纤维性骨发育不良、粘液上皮(mucoepithelial)发育不良、多发性骺发育不全(multiple epiphysial dysplasia)、眼耳脊椎发育不良、眼牙指发育不全、眼椎骨发育不全、牙源性发育不良、眼下颌骨发育不良、根尖周牙骨质发育不良、多骨纤维结构不良、假性软骨发育不全性脊椎骺发育不良、视网膜发育不良、眼及透明隔发育不良、脊椎骺发育不良和室挠骨(ventriculoradial)发育不良。
化生是受控细胞生长的一种形式,其中一种类型的成熟细胞或完全分化的细胞取代另一类型的成熟细胞。根据本发明的用途可检测的化生疾病优选地选自特发性骨髓外化生、大汗腺化生(apocrine metaplasia)、非典型化生(atypical metaplasia)、自实质性(autoparenchymatous)化生、结缔组织化生、上皮化生、肠化生、化生性贫血、化生性骨化、化生性息肉、骨髓外化生、原发性骨髓外化生、继发性骨髓外化生、鳞状化生、羊膜鳞状化生、症状性骨髓外化生和再生性化生。
根据本发明的用途可检测的眼病优选地选自沙眼、早产儿视网膜病、糖尿病性视网膜病、新生血管性青光眼和老年黄斑变性。
子宫内膜异位症是妇科疾病,其定义为子宫内膜组织在子宫腔外的增生。增生的子宫内膜细胞可分布于整个机体,已经在肺和其他器官中发现了子宫内膜损伤,就此而言子宫内膜损伤的分布类似于微转移的分布。在本发明的用途的优选实施方案中,被检测的子宫内膜损伤例如损伤,例如子宫内膜细胞簇(cell cluster)是血源性细胞簇、腔细胞簇、管腔内细胞簇、淋巴细胞簇、局部细胞簇和/或区域细胞簇。
本发明的用途可用于常规诊断,即用于筛查各自指出的疾病。然而,在又一实施方案中,一旦在用例如标准x射线操作如乳房X线照相术、全身扫描或MRI诊断疾病后,就使用所述缀合物。接着检查患者的转移和/或小的(另外的)原发性肿瘤。为了更好地评价严重度,例如所述疾病的阶段,或为确定最佳治疗选择和/或在治疗操作(例如药物、放射或手术)之前、过程中和/或之后,可进行这样的检查。如果在一种治疗操作之前进行,由于其高度的灵敏度,本发明的用途允许确定例如是否已在原发性肿瘤附近形成了转移,并因此更好地确定治疗方案,如在乳腺癌中是否指示了肿块切除或宁可乳房切除。
在治疗后,本发明的诊断操作的用途允许评价治疗操作的成功,并确定随后的治疗方案,例如放射或化疗。当在手术操作中使用时,例如可能检测所述原发性肿瘤附近的组织如淋巴结中的转移。在该实施方案中,本发明的用途允许更完全地在手术操作期间除去肿瘤或转移。
在本发明的用途的另一方面,所述诊断组合物还包含药学可接受的物质,例如用于调节渗透压的药学可接受的盐、缓冲剂、防腐剂、载体和/或赋形剂。优选地,所述诊断组合物以无热原的胃肠外可接受的药物剂型的形式提供,其可为水溶液或在给药前重配的冻干物(lyophilisate)。需要考虑pH等渗性、稳定性等的这样的药物组合物的制备在本领域的现有技术内。本发明所用的诊断组合物可包含药学可接受的稀释剂,例如氯化钠注射液和林格氏注射液。对于向人给药,所述组合物可在自体血清或血浆中给药。
在本发明的优选的用途中,将所述诊断化合物胃肠外给药,且更优选静脉内给药。在静脉内给药本发明可用的化合物,特别是SF64、5-29、5-36和5-41后,能够在大约几分钟内发生体内成像。然而,如果需要,能够在本发明可用的化合物,特别是在SF64、5-29、5-36和/或5-41被注射到所述患者体内后几小时,或者甚至更长的时间后发生成像。在大多数情况下,足量的给药剂量将在约0.1小时内蓄积于待成像的区域内。当使用本发明可用的化合物,特别是SF64、5-29、5-36和/或5-41时,已惊讶地发现,所述造影剂允许在注射后上至48h成像肿瘤。这是超过现有技术的染料的另外的优点,因为它允许在使用DOT之前一天或甚至两天,例如通过患者的专职医师给药本发明可用的化合物,然后允许立即在专门的筛查设备上对所述患者进行成像,而不需要在所述筛查设备上注射染料,也不需要在执行DOT的当天分配所述造影剂。因此,在优选实施方案中,至少在成像之前2、3、4、5、6、7、8、9、10、11、12、13、14、15、16、17、18、19、20、21、22、23、24、25、26、27、28、29、30、31、32、33、34、35、36、37、38、39、40、41、42、43、44、45、46、47或48h给药所述诊断化合物。
如上所述,已惊讶地发现,与关于其他菁染料如ICG所报道的量相比,远远更低量的本发明可用的菁染料,特别是SF64、5-29、5-36和/或5-41足以提供用于检测增生性疾病所需的灵敏度和特异性。但是,在本发明用途的优选实施方案中,诊断组合物中包含的式(I)的化合物的量为约0.4、约0.3、约0.2、0.1、小于0.1、约0.09、约0.08、约0.07、约0.06、约0.05、约0.04、约0.03、约0.02和约0.01mg/kg体重。因此,本发明可用的化合物,特别是SF64、5-29、5-36和/或5-41的优选给药范围为0.4和0.001mg/kg体重之间、0.2和0.001mg/kg体重之间、0.1和0.001mg/kg体重之间、小于0.1和0.001mg/kg体重之间、0.09和0.001mg/kg体重之间、0.008和0.001mg/kg体重之间、0.06和0.001mg/kg体重之间、0.05和0.001mg/kg体重之间。由于本发明的化合物,特别是SF64、5-29、5-36和/或5-41的高亲水性和高水溶性,对患者的注射体积能够低至1ml,这远远小于目前使用的超过10ml的注射液。因此,在本发明用途的优选实施方案中,式(I)的化合物被包含在小于5ml、优选小于4ml、优选小于3ml、优选小于2ml和甚至更优选约1ml的诊断组合物中。
本发明的又一方面是包含用于制备诊断组合物的量的式(I)和/或(III)至(VI)的化合物和任选的上述药学可接受的盐、载体、赋形剂和/或缓冲剂的诊断试剂盒,所述诊断组合物用于每次诊断施用给药小于0.5和0.001mg/kg体重之间、优选地在0.4和0.001mg/kg体重之间、在0.2和0.001mg/kg体重之间、在0.1和0.001mg/kg体重之间、在小于0.1和0.001mg/kg体重之间、在0.09和0.001mg/kg体重之间、在0.008和0.001mg/kg体重之间、在0.06和0.001mg/kg体重之间、在0.05和0.001mg/kg体重之间的所述化合物。优选地,所述试剂盒包括冻干形式的所述化合物和任选的其他成分。
无需进一步说明,相信本领域技术人员使用前面的描述能够最大范围地利用本发明。因此,下列优选的具体实施方案将理解为仅是说明性的,且无论如何不以任何方式限制本公开。
附图简述
图1:右侧乳房患有侵入性乳腺癌的女性患者静脉注射SF64后的光学的乳房X线照相术。亮点由显著的SF64荧光信号引起,在静脉注射后,SF64的确在该侵入性乳腺癌中积聚。
图2:在物质给药6h后,实验性子宫内膜异位的微转移的体外成像实例。左图显示荧光染料的结构,右图显示子宫内膜组织准备的图像。所述图像包括指示厘米尺寸比例的标尺。
图3:在物质给药6h后,皮肤的自发性微小损伤的体内成像实例。图A显示原始图像,图B显示反转的图像。所述图像包括指示厘米尺寸比例的标尺。
实施例
右侧乳房患有侵入性乳腺癌的女性患者静脉注射SF64后的光学乳房X线照相术
在用0.9%生理盐水稀释冻干物后,通过留置的前臂导管静脉注射剂量为0.1mg/kg体重的SF64。用光学计算机断层激光乳房X线照相装置对患者成像,患者处于俯卧位,使她的乳房自由垂在成像室内,被空气环绕。开始获得图像。
在SF64经静脉注射1小时10分钟后,使用荧光模式进行图像重建,从而几乎仅显示SF64的荧光信号。所述造影染料的确在该侵入性乳腺癌中积聚,其在图像中由亮点表示。这导致所述图像中显著的SF64荧光信号。
确定几种三碳菁染料的荧光量子产率
在水或血浆中,测试化合物6-4、5-36、5-29、5-41、NIR96009、NIR96005和ICG(参见表1)在2μM的浓度时的荧光量子产率。从表2中显而易见的是,三碳菁染料中部的取代改善了在两种介质中的荧光量子产率。
表1
表2
化合物(#) | 血浆中的最大荧光(nm) | 血浆中的荧光量子产率(%) | 水中的荧光量子产率(%) | 备注 |
L4=烷基取代的化合物 | ||||
6-4 | 787 | 17 | 11 | |
5-36 | 787 | 17 | 12 | |
5-29 | 813 | 9.8 | 8.2 | |
5-41 | 799 | 19 | 10 | |
L4没有烷基取代的化合物 | ||||
NIR96009 | 786 | 7.8 | 5.8 | *参见文献 |
NIR96005 | 795 | 7.2 | 5.6 | *参见文献 |
ICG | 829 | 3 | 1 | *参见文献 |
·Licha等人,Proceedings of the SPIE Vol.2927(Bellingham,VA,US),1996,p.192-198
患有Capan-1肿瘤的裸鼠中的微转移成像
将在培养物中亚汇合地(subconfluently)生长的Capan-1肿瘤细胞胰蛋白酶化,离心并再悬浮于PBS中。在用锥虫蓝染色并计算细胞浓度后,将细胞悬浮液的浓度设置为3×107/ml。将所述细胞悬液在冰上冷却直到使用。麻醉三只雌性裸鼠(NMRI裸鼠,体重24-25g),在切开腹部后,将30μl(1×106细胞/动物)细胞悬液囊下接种到各只动物的胰腺中。每只动物接受0.05μmol/kg体重(0.04mg染料/kg体重)的包括具有图2所示结构的菁染料的物质,其已经被缀合到EB-DF抗体AP39上(参见Marty C等人(2001)Protein Expr.Purif.21:156-64)。在可触知明确的肿瘤生长的时间点(在肿瘤细胞植入后约12至14周)静脉内给药该物质。在静脉内物质给药6小时后处死动物,并用增强型CCD相机在体外拍摄包含微转移的肠系膜的荧光信号。通过用波长为740nm的近红外光照射肠系膜来激发所述物质的荧光,用激光二极管(0.5W输出)产生所述近红外光。数字化地贮存荧光图像。然后,用低倍率显微镜(Stemi 2000-C,Fa.Carl Zeis)测定微转移的尺寸。从0.5至2.0mm直径范围的微转移和从更大的肠系膜转移接收荧光信号,并使其与显微镜的测定对应。在图2的右图中描述了所述染料缀合物的效力。
裸鼠中皮肤的自发性微小损伤的体内成像
在两只NMRI裸鼠中观察皮肤的自发性的多个微小损伤。每只小鼠静脉内接受0.05μmol/kg体重(0.04mg染料/kg b.w.)的染料-AP39缀合物,所述缀合物如图2所示。在物质给药后6小时,在麻醉的小鼠中进行成像。用吸入麻醉剂异氟烷(Isofluran Curamed,Curamed PharmaGmbH,Karlsruhe,Germany)诱导短时麻醉。通过二极管激光器激发所述物质的荧光(激发波长742nm,激光二极管,0.5W输出),并用增强型CCD相机检测。数字化地保存荧光图像。然后,用低倍率显微镜(Stemi2000-C,Fa.Carl Zeis)测定所述微小损伤的尺寸。从上至小于<1mm的微小损伤接收荧光信号。在基于代表性实施例的图3中显示了所述染料缀合物的效力。
Claims (15)
2.根据权利要求1所述的用途,其中所述化合物与靶向化合物偶联。
3.根据权利要求2所述的用途,其中所述靶向化合物选自由多肽、核酸、小分子或糖组成的靶向化合物的组。
4.根据权利要求1至3中任一项所述的用途,其中所述多肽选自受体配体、抗体、单链抗体或者抗体或单链抗体的结合片段。
5.根据权利要求1至4中任一项所述的用途,其中所述增生性疾病选自肿瘤、初癌状态、发育不良、化生、银屑病、银屑病关节炎、类风湿性关节炎、子宫内膜异位症和/或眼病。
6.根据权利要求5所述的用途,其中所述肿瘤为原发性肿瘤或转移。
7.根据权利要求6所述的用途,其中所述肿瘤为胃肠道或结肠直肠道的恶性瘤、肝癌、胰腺癌、肾癌、膀胱癌、甲状腺癌、前列腺癌、子宫内膜癌、卵巢癌、睾丸癌、黑素瘤、口腔粘膜发育异常、侵入性口腔癌、小细胞或非小细胞肺癌;乳房肿瘤,包括激素依赖性乳腺癌、激素非依赖性乳腺癌;移行细胞癌和鳞状细胞癌;神经恶性肿瘤,包括神经母细胞瘤、神经胶质瘤、星形细胞瘤、骨肉瘤、脑膜瘤;软组织肉瘤;血管瘤和内分泌肿瘤,包括垂体腺瘤、嗜铬细胞瘤、副神经节瘤、包括淋巴瘤和白血病的恶性血液病,或者源自上述肿瘤中的一种的转移。
8.根据权利要求6所述的用途,其中所述诊断化合物是在肿瘤筛查期间,或者在手术前、手术期间或手术后给药的。
9.根据权利要求5所述的用途,其中所述初癌状态选自皮肤的初癌状态,特别是光化性角化病、皮角、光化性唇炎、焦油角化病、砷角化病、x射线角化病、鲍恩病、鲍恩样丘疹病、恶性雀斑样痣、硬化性苔藓和粘膜红苔藓;消化道的初癌状态,特别是粘膜红斑、白斑、巴雷特食管、普-文综合征、脚溃疡、过度生长的胃肥大、边缘癌、瘤形成的肠息肉、直肠息肉、瓷胆囊;妇科的初癌状态,特别是原位导管癌(CDIS)、宫颈上皮内瘤样病变(CIN)、白斑、子宫内膜增生(III级)、外阴营养不良、外阴上皮内瘤样病变(VIN)、葡萄胎;泌尿科的初癌状态,特别是膀胱乳头状瘤病、凯拉增殖性红斑、睾丸上皮内瘤样病变(TIN)、白斑;原位癌(CIS);由慢性炎症,特别是脓皮病、骨髓炎、聚合性痤疮、寻常狼疮和瘘引起的初癌状态。
10.根据权利要求5所述的用途,其中所述化生选自特发性骨髓外化生、大汗腺化生、非典型化生、自实质性化生、结缔组织化生、上皮化生、肠化生、化生性贫血、化生性骨化、化生性息肉、骨髓外化生、原发性骨髓外化生、继发性骨髓外化生、鳞状化生、羊膜鳞状化生、症状性骨髓外化生和再生性化生。
11.根据权利要求5所述的用途,其中所述发育不良选自先天性外胚层发育不全、前颜面发育异常、窒息性胸廓发育不良、心-指发育不良、支气管肺发育不良、脑发育不良、宫颈结构不良、软骨外胚层发育不良、锁颅发育不全、先天性外胚层发育不良、颅面骨干发育不全、颅腕跖骨发育不全、颅干骺发育不全、牙本质发育异常、骨干发育不全、外胚层发育不良、釉质发育异常、脑眼球发育不全、骺发育不全半肢畸形、多发性骨骺发育不良、点状骨骺发育不良、上皮异常增生、面-指-生殖器发育不良、家族性颌骨纤维性结构不良、家族性白色皱襞性发育不良、肌纤维结构不良、骨纤维性结构不良、红润色骨发育不全、遗传性肾-视网膜发育不良、多汗性外胚层发育不良、少汗性外胚层发育不全、淋巴细胞减少性胸腺发育不全、乳腺结构不良、下颌骨颜面发育不良、骨骺端发育不全、Mondini畸形、单骨纤维性骨发育不良、粘液上皮发育不良、多发性骺发育不全、眼耳脊椎发育不良、眼牙指发育不全、眼椎骨发育不全、牙源性发育不良、眼下颌骨发育不良、根尖周牙骨质发育不良、多骨纤维结构不良、假性软骨发育不全性脊椎骺发育不良、视网膜发育不良、眼及透明隔发育不良、脊椎骺发育不良和室挠骨发育不良。
12.根据权利要求5所述的用途,其中所述眼病选自沙眼、早产儿视网膜病、糖尿病性视网膜病、新生血管性青光眼和老年黄斑变性。
13.根据权利要求1至12中任一项所述的用途,其中所述诊断组合物还包含药学可接受的盐、载体、赋形剂和/或缓冲剂。
14.根据权利要求1至13中任一项所述的用途,其中所述化合物以0.1mg/kg体重或更低的量被包含在所述诊断组合物中。
15.一种诊断试剂盒,其包含制备诊断组合物的量的根据权利要求1所述的式(I)的化合物或其药学可接受的盐与任选的药学可接受的盐、载体、赋形剂和/或缓冲剂,所述诊断组合物用于每次诊断施用给药小于0.5并大于0.001mg/kg体重的所述化合物。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05000276.5 | 2005-01-07 | ||
EP05000276A EP1679082A1 (en) | 2005-01-07 | 2005-01-07 | Use of cyanine dyes for the diagnosis of proliferative diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
CN101128218A true CN101128218A (zh) | 2008-02-20 |
Family
ID=34933224
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA2006800014277A Pending CN101128218A (zh) | 2005-01-07 | 2006-01-05 | 菁染料用于诊断增生性疾病的用途 |
Country Status (23)
Country | Link |
---|---|
EP (2) | EP1679082A1 (zh) |
JP (1) | JP5578765B2 (zh) |
KR (1) | KR20070092270A (zh) |
CN (1) | CN101128218A (zh) |
AR (1) | AR052190A1 (zh) |
AU (1) | AU2006204496A1 (zh) |
BR (1) | BRPI0606411A2 (zh) |
CA (1) | CA2594390C (zh) |
CR (1) | CR9232A (zh) |
DO (1) | DOP2006000005A (zh) |
GT (1) | GT200600001A (zh) |
IL (1) | IL182499A0 (zh) |
MX (1) | MX2007008300A (zh) |
NO (1) | NO20074036L (zh) |
NZ (1) | NZ554917A (zh) |
PA (1) | PA8659101A1 (zh) |
PE (2) | PE20060872A1 (zh) |
RU (1) | RU2007129919A (zh) |
TW (1) | TW200635612A (zh) |
UA (1) | UA89976C2 (zh) |
UY (1) | UY29323A1 (zh) |
WO (1) | WO2006072580A1 (zh) |
ZA (1) | ZA200706533B (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102608051A (zh) * | 2012-02-21 | 2012-07-25 | 中国科学院化学研究所 | 用于诊断白血病的试剂盒 |
CN102703569A (zh) * | 2012-05-24 | 2012-10-03 | 中国科学院化学研究所 | 菁染料的新用途 |
CN102706787A (zh) * | 2012-05-24 | 2012-10-03 | 中国科学院化学研究所 | 菁染料的新用途 |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE602004009169D1 (de) * | 2004-07-22 | 2007-11-08 | Bayer Schering Pharma Ag | Verwendung von Cyanin-farbstoffen zur Diagnose von Krankheiten, welche mit Angiogenese assoziert sind |
EP1679082A1 (en) * | 2005-01-07 | 2006-07-12 | Schering AG | Use of cyanine dyes for the diagnosis of proliferative diseases |
EP1743658A1 (en) * | 2005-07-14 | 2007-01-17 | Schering Aktiengesellschaft | Optical imaging of rheumatoid arthritis |
CN101636412A (zh) * | 2007-03-30 | 2010-01-27 | 霍夫曼-拉罗奇有限公司 | 标记的和非标记的单克隆抗体的组合物 |
WO2009012109A2 (en) | 2007-07-13 | 2009-01-22 | Emory University | Cyanine-containing compounds for cancer imaging and treatment |
GB0803477D0 (en) | 2008-02-26 | 2008-04-02 | Ge Healthcare As | Therapy selection method |
CN105288645A (zh) * | 2008-06-13 | 2016-02-03 | 西塞医疗中心 | 用于癌症靶向治疗的小分子配体-药物轭合物 |
GB0814960D0 (en) * | 2008-08-15 | 2008-09-24 | Ge Healthcare As | Method for detecting dysplasia |
WO2011003996A1 (en) | 2009-07-09 | 2011-01-13 | F. Hoffmann-La Roche Ag | In vivo tumor vasculature imaging |
US20120230918A1 (en) | 2009-07-28 | 2012-09-13 | Hoffmann-La-Roche Inc. | Non-invasive in vivo optical imaging method |
DK2470887T3 (da) | 2009-08-28 | 2020-04-06 | Visen Medical Inc | Systemer til tomografisk billeddannelse i diffuse medier ved at anvende en hybrid inversionsteknik |
JP2011046662A (ja) | 2009-08-28 | 2011-03-10 | Fujifilm Corp | 近赤外蛍光造影剤 |
JP2011046663A (ja) | 2009-08-28 | 2011-03-10 | Fujifilm Corp | 近赤外蛍光造影剤 |
US8401619B2 (en) | 2009-09-22 | 2013-03-19 | Visen Medical, Inc. | Systems and methods for virtual index-matching of diffusive media |
EP2567234B1 (en) | 2010-05-07 | 2018-09-19 | F.Hoffmann-La Roche Ag | Diagnostic method for the detection of cells ex vivo |
WO2012120004A1 (en) | 2011-03-07 | 2012-09-13 | F. Hoffmann-La Roche Ag | In vivo selection of therapeutically active antibodies |
US20140099264A1 (en) | 2011-03-07 | 2014-04-10 | F. Hoffman-La Roche Ag | Means and methods for in vivo testing of therapeutic antibodies |
KR101373108B1 (ko) | 2012-01-20 | 2014-03-27 | 이화여자대학교 산학협력단 | 폴리메틴 체인에 메조-반응작용기를 갖는 신규한 시아닌 유도체 및 이의 제조방법 |
EP2906106B1 (en) | 2012-10-15 | 2023-06-14 | VisEn Medical, Inc. | Systems, methods, and apparatus for imaging of diffuse media featuring cross-modality weighting of fluorescent and bioluminescent sources |
WO2014065439A1 (en) * | 2012-10-26 | 2014-05-01 | Canon Kabushiki Kaisha | Cancer cell inhibitory drug and cancer stem-cell detection probe |
WO2014092958A1 (en) * | 2012-12-10 | 2014-06-19 | Molecular Targeting Technologies, Inc. | Compositions and methods of diagnosing ocular diseases |
CN113349707A (zh) | 2013-12-31 | 2021-09-07 | 纪念斯隆-凯特琳癌症中心 | 用于荧光源实时多通道成像的系统、方法和设备 |
RU2565645C1 (ru) * | 2014-09-05 | 2015-10-20 | Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации | Способ рентгендиагностики глубины инвазии рецидива рака вульвы в мягкие ткани |
US10335501B2 (en) | 2014-12-15 | 2019-07-02 | Memorial Sloan Kettering Cancer Center | Cyclic peptides with enhanced nerve-binding selectively, nanoparticles bound with said cyclic peptides, and use of same for real-time in vivo nerve tissue imaging |
US20190090750A1 (en) | 2015-12-15 | 2019-03-28 | Memorial Sloan Kettering Cancer Center | Imaging systems and methods for tissue differentiation, e.g., for intraoperative visualization |
US11660354B2 (en) | 2016-11-30 | 2023-05-30 | Memorial Sloan Kettering Cancer Center | Inhibitor-functionalized ultrasmall nanoparticles and methods thereof |
CA3095410A1 (en) | 2018-03-30 | 2019-10-03 | Perkinelmer Health Sciences, Inc. | Systems and methods for 3d reconstruction of anatomical organs and inclusions using short-wave infrared (swir) projection tomography |
EP4015004A1 (en) | 2020-12-18 | 2022-06-22 | Phi Pharma SA | Proteoglycan specific branched peptides |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000095758A (ja) * | 1998-09-18 | 2000-04-04 | Schering Ag | 近赤外蛍光造影剤および蛍光造影方法 |
DE19917713A1 (de) * | 1999-04-09 | 2000-10-19 | Diagnostikforschung Inst | Kurzkettige Peptid-Farbstoffkonjugate als Konstrastmittel für die optische Diagnostik |
DE19947559A1 (de) * | 1999-09-24 | 2001-04-19 | Schering Ag | Antikörper-Farbstoffkonjugate gegen Zielstrukturen der Angiogenese zur intraoperativen Tumorranddarstellung |
PL376459A1 (en) * | 2003-01-24 | 2005-12-27 | Schering Ag | Hydrophilic, thiol-reactive cyanine dyes and conjugates thereof with biomolecules for fluorescence diagnosis |
DE602004009169D1 (de) * | 2004-07-22 | 2007-11-08 | Bayer Schering Pharma Ag | Verwendung von Cyanin-farbstoffen zur Diagnose von Krankheiten, welche mit Angiogenese assoziert sind |
EP1679082A1 (en) * | 2005-01-07 | 2006-07-12 | Schering AG | Use of cyanine dyes for the diagnosis of proliferative diseases |
-
2005
- 2005-01-07 EP EP05000276A patent/EP1679082A1/en not_active Withdrawn
-
2006
- 2006-01-02 UY UY29323A patent/UY29323A1/es not_active Application Discontinuation
- 2006-01-03 DO DO2006000005A patent/DOP2006000005A/es unknown
- 2006-01-04 GT GT200600001A patent/GT200600001A/es unknown
- 2006-01-05 PE PE2006000039A patent/PE20060872A1/es not_active Application Discontinuation
- 2006-01-05 MX MX2007008300A patent/MX2007008300A/es not_active Application Discontinuation
- 2006-01-05 KR KR1020077015555A patent/KR20070092270A/ko not_active Application Discontinuation
- 2006-01-05 BR BRPI0606411-6A patent/BRPI0606411A2/pt not_active IP Right Cessation
- 2006-01-05 JP JP2007549858A patent/JP5578765B2/ja active Active
- 2006-01-05 PE PE2010000020A patent/PE20100449A1/es not_active Application Discontinuation
- 2006-01-05 CA CA2594390A patent/CA2594390C/en active Active
- 2006-01-05 NZ NZ554917A patent/NZ554917A/en unknown
- 2006-01-05 CN CNA2006800014277A patent/CN101128218A/zh active Pending
- 2006-01-05 EP EP06700474A patent/EP1833513B1/en active Active
- 2006-01-05 AU AU2006204496A patent/AU2006204496A1/en not_active Abandoned
- 2006-01-05 WO PCT/EP2006/000058 patent/WO2006072580A1/en active Application Filing
- 2006-01-05 UA UAA200708556A patent/UA89976C2/ru unknown
- 2006-01-05 RU RU2007129919/15A patent/RU2007129919A/ru not_active Application Discontinuation
- 2006-01-06 TW TW095100548A patent/TW200635612A/zh unknown
- 2006-01-06 AR ARP060100046A patent/AR052190A1/es unknown
- 2006-01-06 PA PA20068659101A patent/PA8659101A1/es unknown
-
2007
- 2007-04-12 IL IL182499A patent/IL182499A0/en unknown
- 2007-07-06 CR CR9232A patent/CR9232A/es not_active Application Discontinuation
- 2007-08-03 NO NO20074036A patent/NO20074036L/no not_active Application Discontinuation
- 2007-08-06 ZA ZA200706533A patent/ZA200706533B/xx unknown
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102608051A (zh) * | 2012-02-21 | 2012-07-25 | 中国科学院化学研究所 | 用于诊断白血病的试剂盒 |
CN102608051B (zh) * | 2012-02-21 | 2015-04-08 | 中国科学院化学研究所 | 用于诊断白血病的试剂盒 |
CN102703569A (zh) * | 2012-05-24 | 2012-10-03 | 中国科学院化学研究所 | 菁染料的新用途 |
CN102706787A (zh) * | 2012-05-24 | 2012-10-03 | 中国科学院化学研究所 | 菁染料的新用途 |
CN102703569B (zh) * | 2012-05-24 | 2014-04-09 | 中国科学院化学研究所 | 菁染料的新用途 |
CN102706787B (zh) * | 2012-05-24 | 2015-04-08 | 中国科学院化学研究所 | 菁染料的新用途 |
Also Published As
Publication number | Publication date |
---|---|
KR20070092270A (ko) | 2007-09-12 |
AU2006204496A1 (en) | 2006-07-13 |
MX2007008300A (es) | 2007-09-07 |
BRPI0606411A2 (pt) | 2009-06-23 |
DOP2006000005A (es) | 2006-07-15 |
ZA200706533B (en) | 2009-07-29 |
CA2594390A1 (en) | 2006-07-13 |
UY29323A1 (es) | 2006-10-02 |
RU2007129919A (ru) | 2009-02-20 |
AR052190A1 (es) | 2007-03-07 |
NO20074036L (no) | 2007-08-03 |
EP1833513A1 (en) | 2007-09-19 |
JP2008526802A (ja) | 2008-07-24 |
EP1833513B1 (en) | 2013-03-06 |
PE20100449A1 (es) | 2010-07-25 |
IL182499A0 (en) | 2007-09-20 |
TW200635612A (en) | 2006-10-16 |
PA8659101A1 (es) | 2006-09-08 |
PE20060872A1 (es) | 2006-10-01 |
GT200600001A (es) | 2006-08-22 |
UA89976C2 (ru) | 2010-03-25 |
JP5578765B2 (ja) | 2014-08-27 |
WO2006072580A1 (en) | 2006-07-13 |
NZ554917A (en) | 2010-01-29 |
EP1679082A1 (en) | 2006-07-12 |
CA2594390C (en) | 2013-10-22 |
CR9232A (es) | 2007-11-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101128218A (zh) | 菁染料用于诊断增生性疾病的用途 | |
US20100166659A1 (en) | Use of cyanine dyes for the diagnosis of proliferative diseases | |
Zhang et al. | Beyond the margins: real-time detection of cancer using targeted fluorophores | |
Korb et al. | Use of monoclonal antibody–IRDye800CW bioconjugates in the resection of breast cancer | |
US20120230918A1 (en) | Non-invasive in vivo optical imaging method | |
CN101022835A (zh) | 用于诊断微转移的与抗体缀合的花青染料 | |
CN102438659A (zh) | 光学成像剂 | |
US20120226119A1 (en) | Vivo tumor vasculature imaging | |
JP2010529060A (ja) | 腫瘍抗原に結合する無標識一次モノクローナル抗体と、nirフルオレセイン標識で標識された非交差反応性二次モノクローナル抗体から成る組成物 | |
AU2015317444B2 (en) | uPAR targeting peptide for use in peroperative optical imaging of invasive cancer | |
JP2010526859A (ja) | ペプチドイメージング剤 | |
CN103402547A (zh) | 开关型荧光纳米颗粒探针以及使用其的荧光分子成像法 | |
Crawford et al. | A scoping review of ongoing fluorescence‐guided surgery clinical trials in otolaryngology | |
JP2012500191A (ja) | 異形成の検出方法 | |
US20060039863A1 (en) | Use of cyanine dyes for the diagnosis of disease associated with angiogenesis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1112690 Country of ref document: HK |
|
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20080220 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1112690 Country of ref document: HK |